The efficacy and safety of rituximab in refractory pemphigus

a review of case reports.

Kattie J. Allen, Stephen Wolverton

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Rituximab is a chimeric murine-human monoclonal antibody that targets the CD20 antigen found on B cells and results in rapid depletion of this cell population. It is indicated for patients with relapsed or refractory, low-grade or follicular, CD20-positive, B cell non-Hodgkin's lymphoma. In addition, rituximab has been used for many other diseases, including refractory pemphigus. In this study, 42 case reports of patients with refractory pemphigus vulgaris, pemphigus foliaceus, and paraneoplastic pemphigus treated with rituximab were reviewed for clinical efficacy and safety. Forty-one of the 42 patients had at least some improvement following the rituximab therapy, while 6 suffered infectious adverse events. Though rituximab appears to be effective in the treatment of refractory pemphigus diseases, further studies are warranted to clarify its overall safety, especially concerning the risk of infectious adverse events in this patient population.

Original languageEnglish
Pages (from-to)883-889
Number of pages7
JournalJournal of drugs in dermatology : JDD
Volume6
Issue number9
StatePublished - Sep 2007

Fingerprint

Pemphigus
Safety
CD20 Antigens
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Population
B-Lymphocytes
Monoclonal Antibodies
Rituximab
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The efficacy and safety of rituximab in refractory pemphigus : a review of case reports. / Allen, Kattie J.; Wolverton, Stephen.

In: Journal of drugs in dermatology : JDD, Vol. 6, No. 9, 09.2007, p. 883-889.

Research output: Contribution to journalArticle

@article{7520c080944d4127854495901b26ecac,
title = "The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.",
abstract = "Rituximab is a chimeric murine-human monoclonal antibody that targets the CD20 antigen found on B cells and results in rapid depletion of this cell population. It is indicated for patients with relapsed or refractory, low-grade or follicular, CD20-positive, B cell non-Hodgkin's lymphoma. In addition, rituximab has been used for many other diseases, including refractory pemphigus. In this study, 42 case reports of patients with refractory pemphigus vulgaris, pemphigus foliaceus, and paraneoplastic pemphigus treated with rituximab were reviewed for clinical efficacy and safety. Forty-one of the 42 patients had at least some improvement following the rituximab therapy, while 6 suffered infectious adverse events. Though rituximab appears to be effective in the treatment of refractory pemphigus diseases, further studies are warranted to clarify its overall safety, especially concerning the risk of infectious adverse events in this patient population.",
author = "Allen, {Kattie J.} and Stephen Wolverton",
year = "2007",
month = "9",
language = "English",
volume = "6",
pages = "883--889",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "9",

}

TY - JOUR

T1 - The efficacy and safety of rituximab in refractory pemphigus

T2 - a review of case reports.

AU - Allen, Kattie J.

AU - Wolverton, Stephen

PY - 2007/9

Y1 - 2007/9

N2 - Rituximab is a chimeric murine-human monoclonal antibody that targets the CD20 antigen found on B cells and results in rapid depletion of this cell population. It is indicated for patients with relapsed or refractory, low-grade or follicular, CD20-positive, B cell non-Hodgkin's lymphoma. In addition, rituximab has been used for many other diseases, including refractory pemphigus. In this study, 42 case reports of patients with refractory pemphigus vulgaris, pemphigus foliaceus, and paraneoplastic pemphigus treated with rituximab were reviewed for clinical efficacy and safety. Forty-one of the 42 patients had at least some improvement following the rituximab therapy, while 6 suffered infectious adverse events. Though rituximab appears to be effective in the treatment of refractory pemphigus diseases, further studies are warranted to clarify its overall safety, especially concerning the risk of infectious adverse events in this patient population.

AB - Rituximab is a chimeric murine-human monoclonal antibody that targets the CD20 antigen found on B cells and results in rapid depletion of this cell population. It is indicated for patients with relapsed or refractory, low-grade or follicular, CD20-positive, B cell non-Hodgkin's lymphoma. In addition, rituximab has been used for many other diseases, including refractory pemphigus. In this study, 42 case reports of patients with refractory pemphigus vulgaris, pemphigus foliaceus, and paraneoplastic pemphigus treated with rituximab were reviewed for clinical efficacy and safety. Forty-one of the 42 patients had at least some improvement following the rituximab therapy, while 6 suffered infectious adverse events. Though rituximab appears to be effective in the treatment of refractory pemphigus diseases, further studies are warranted to clarify its overall safety, especially concerning the risk of infectious adverse events in this patient population.

UR - http://www.scopus.com/inward/record.url?scp=38449088869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449088869&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 883

EP - 889

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 9

ER -